menu
    • menu

    Company profile for Avilar Therapeutics

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    At Avilar, we are moving beyond the boundaries of the cell to pioneer the discovery and development of extracellular protein degraders. Our ATACs (ASGPR Targeting Chimeras) are a new class of protein degrader therapeutics that shuttle disease-causing proteins from the circulation to the endolysosome where they are degraded.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Avilar TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    400 Totten Pond Road, Suite 110 Waltham, MA 02451
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://avilar-tx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/avilar-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Avilar_Tx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Avilar: MTAC Protein Degrader Preclinical Data At AAI Meeting
    Avilar: MTAC Protein Degrader Preclinical Data At AAI Meeting

    01 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240501555976/en

    BUSINESSWIRE
    01 May 2024
    Share Share
    Avilar Receives U.S. Patent for Novel Extracellular Protein Degraders
    Avilar Receives U.S. Patent for Novel Extracellular Protein Degraders

    27 Nov 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231127925735/en

    BUSINESSWIRE
    27 Nov 2023
    Share Share
    Avilar Therapeutics to Present New Data for ATAC Extracellular Protein Degraders
    Avilar Therapeutics to Present New Data for ATAC Extracellular Protein Degraders

    30 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231030997970/en

    BUSINESSWIRE
    30 Oct 2023
    Share Share
    Avilar Therapeutics to Present at Upcoming Industry Conferences
    Avilar Therapeutics to Present at Upcoming Industry Conferences

    19 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230919904070/en

    BUSINESSWIRE
    19 Sep 2023
    Share Share
    Avilar Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference
    Avilar Therapeutics to Present at the 2023 Wells Fargo Healthcare Conference

    30 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230830174389/en

    BUSINESSWIRE
    30 Aug 2023
    Share Share
    Sanofi, Astellas venture arms add cash to Avilar's 'ATAC' mission
    Sanofi, Astellas venture arms add cash to Avilar's 'ATAC' mission

    16 Feb 2023

    // Kyle LaHucik ENDPTS

    https://endpts.com/exclusive-sanofi-astellas-venture-arms-add-cash-to-avilars-atac-mission/

    Kyle LaHucik ENDPTS
    16 Feb 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search